AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
FROM THE WIRE · FINANCE.YAHOO.COM
AbbVie (ABBV) raised its 2026 guidance on Friday as the biopharmaceutical company's immunology and n Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT Newswires articles Stock picks Expert picks…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised guidance from a large pharma company is relevant for the stock and the healthcare sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AbbVie raised its 2026 guidance on Friday.
- 02Quarterly immunology and neuroscience sales beat expectations.
- 03The available text gives no further numerical details.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets